{
  "pmcid": "2590635",
  "sha256": "602dea4a3568352aaa12208ad42f42353b34dca69cfe2a0572f672bcd4b70033",
  "timestamp_utc": "2025-11-09T23:45:08.986712+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.404322916666668,
    "reading_ease": 31.461163194444453,
    "word_count": 256
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Continuous Lumbar Plexus Block Duration After Hip Arthroplasty"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were then randomly assigned to continue ropivacaine or switch to normal saline."
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients undergoing hip arthroplasty were enrolled"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were then randomly assigned to continue ropivacaine or switch to normal saline."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial evaluated whether a 4-day ambulatory continuous lumbar plexus block (cLPB) enhances ambulation distance and shortens time to meet discharge criteria compared to an overnight cLPB following hip arthroplasty."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcomes were time to meet three discharge criteria (adequate analgesia, independence from intravenous analgesics, ambulation â‰¥ 30 m) and ambulation distance in 6 minutes the afternoon after surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 2,
        "evidence": "Blinding included patients and outcome assessors."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "A total of 47 patients were randomised: 24 to the ropivacaine group and 23 to the control group"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "analysis conducted on an intention-to-treat basis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The ropivacaine group met discharge criteria in a median of 29 hours (25th-75th percentiles: 24-45) compared to 51 hours (42-73) in the control group (estimated ratio = 0.62; 95% CI, 0.45-0.92; P = 0.011)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events included three falls in the ropivacaine group (13%), with none in the control group."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Trial registration: [Number]."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [Source]."
      }
    },
    "total_score": 19,
    "max_score": 25
  }
}